Proteomics firm Cellzome said this week it has entered into a joint project with Pfizer to use its Episphere chemoproteomics platform to investigate epigenetic factors involved in stem cell regulation.
The company will work with Pfizer's Pain & Sensory Disorders and Regenerative Medicine unit on the project. Cellzome is also currently involved in an epigenetics collaboration with GlaxoSmithKline using the Episphere platform screen for epigenetic drug targets related to undisclosed immuno-inflammatory diseases.
That deal netted the company a $45 million upfront payment and the potential to earn more than $645 million in milestone payments, two of which it has received in recent months (PM 02/11/2011).
According to a Cellzome spokesperson, the Pfizer project is expected to run for several months, possibly until the end of the year.
Financial and other terms of the agreement were not disclosed.